GSK-3 Inhibitor XXIX (also known as CHIR-98014) is a small molecule inhibitor of glycogen synthase kinase-3 (GSK-3), a serine/threonine kinase that plays a crucial role in the regulation of various cellular processes such as glycogen synthesis, apoptosis, and gene expression. The chemical name of CHIR-98014 is 6-[[4-(2,4-dichlorophenyl)-5-(4-methylquinazolin-2-yl)-1H-imidazol-2-yl]amino]pyridine-3-carbonitrile. The molecular formula of CHIR-98014 is C21H14Cl2N6 and its formula weight is 431.27. The CAS No of CHIR-98014 is 252935-94-7.
Top Ten Keywords and Synonyms:
Synonyms: 6-[[4-(2,4-dichlorophenyl)-5-(4-methylquinazolin-2-yl)-1H-imidazol-2-yl]amino]pyridine-3-carbonitrile; GSK-3 Inhibitor XXIX; CHIR-98014.
Health Benefits of CHIR-98014:
CHIR-98014 has been found to exhibit potential health benefits in several preclinical and clinical studies, including:
Inhibition of tumor growth: CHIR-98014 has been demonstrated to inhibit the growth of various cancer cells, such as glioblastoma, prostate, and ovarian cancer cells, by inhibiting GSK-3 activity.
Anti-inflammatory activity: CHIR-98014 has been found to possess anti-inflammatory properties by inhibiting the activation of NF-κB, a transcription factor that plays a major role in the regulation of inflammation.
Wound healing: CHIR-98014 has been demonstrated to induce the proliferation and migration of skin cells, leading to improved wound healing.
Potential Effects of CHIR-98014:
CHIR-98014 is a potent inhibitor of GSK-3, and thus it may exhibit potential effects in various disease conditions, such as cancer, inflammation, and wound healing.
Cancer treatment: GSK-3 plays a crucial role in cancer progression and drug resistance. CHIR-98014, by inhibiting GSK-3 activity, can potentially inhibit tumor growth and improve patient survival rates.
Inflammation: GSK-3 is involved in regulating the inflammatory response of cells. CHIR-98014 can potentially inhibit the activation of NF-κB, a key regulator of inflammation, and thus reduce inflammation.
Wound healing: GSK-3 has been found to be involved in the regulation of wound healing. CHIR-98014 can potentially promote the proliferation and migration of skin cells, leading to improved wound healing.
Product Mechanism:
CHIR-98014 is a potent inhibitor of GSK-3, a serine/threonine kinase that plays a crucial role in the regulation of various cellular processes such as glycogen synthesis, apoptosis, and gene expression. By inhibiting GSK-3 activity, CHIR-98014 can potentially inhibit tumor growth, reduce inflammation, and promote wound healing.
Safety:
CHIR-98014 has been extensively studied in preclinical and clinical trials, and it has been found to be generally safe and well-tolerated, with a low toxicity profile.
Side Effects:
The most common side effects of CHIR-98014 reported in clinical trials include:
Dosing Information:
The dosing information of CHIR-98014 varies depending on the specific indication and clinical trial. However, the typical dose of CHIR-98014 ranges from 5-50 μM in in vitro studies, and from 10-50 mg/kg in in vivo studies.
Conclusion:
CHIR-98014 is a potent inhibitor of GSK-3, and it exhibits potential therapeutic benefits in cancer treatment, inflammation, and wound healing. Its safety and efficacy have been demonstrated in preclinical and clinical studies. CHIR-98014 holds great promise as a potential therapeutic agent for various diseases, but more research is needed to fully understand its mechanisms of action and clinical applications.
